<DOC>
	<DOCNO>NCT02033863</DOCNO>
	<brief_summary>To collect confirmatory data support safety performance ArtVentive Medical Group Endoluminal Occlusion System .</brief_summary>
	<brief_title>Evaluation PerformanCe Peripheral EOS Treatment Varicocele Pelvic Congestion SynDromE</brief_title>
	<detailed_description>Prospective , non-randomized , multi-center confirmatory observational study treatment subject need vascular occlusion follow condition : 1 . Cohort A : Varicocele arise spermatic vein ( ) pampiniform plexus , without concomitant diagnosis infertility subfertility 2 . Cohort B : Pelvic varix female treatment pelvic congestion syndrome ( e.g. , pelvic venous incompetence ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Varicocele</mesh_term>
	<criteria>1 . Subjects age ≥18 ≤75 year . 2 . Subject target vessel 3.0 mm 12.0 mm diameter . 3 . Subject indication undergo embolotherapy consistent clinical preprocedural angiographic assessment spermatic vein origin varicocele ( unilateral and/or bilateral ) pelvic congestion syndrome ( pelvic venous incompetence ) . 4 . Subject able willing comply site standard medical followup , include one month followup visit . 5 . Subject subject 's legal representative inform nature study , agree participate sign consent form . 1 . Subject active systemic infection . 2 . Subject know allergy iodinate contrast adequately premedicated . 3 . Subject history stroke within prior 6 month . 4 . Subject history myocardial infarction prior 3 month . 5 . Subject acute chronic renal disease ( e.g. , measure serum creatinine &gt; 2.5 mg/dL &gt; 220 umol/L ) , dialysis . 6 . Subject know coagulopathy bleeding diatheses , thrombocytopenia platelet count less 100,000/microliter , INR &gt; 1.5 . 7 . Comorbid condition place subject unacceptable surgical risk ( e.g. , severe chronic obstructive pulmonary disease , hepatic failure , cardiac disease , autoimmune disorder condition severe immunosuppression ) . 8 . Subjects venography arteriography contraindicate . 9 . Subjects know hypersensitivity contraindication nickel nitinol . 10 . Subject less one year life expectancy . 11 . Subject pregnant breastfeeding . 12 . Subject endometriosis ovarian / uterine pathology adhesion would interfere endpoint study . 13 . Subject previous pelvic surgical intervention embolotherapy varicocele ovarian varix would interfere endpoint study , include limited , recurrent varicocele ovarian varix . 14 . Any clinical evidence investigator feel would place subject increase risk deployment device . 15 . Subject plan concomitant procedure time embolization ( e.g. , coil embolization , etc. ) . 16 . Subject participate another study device , medication , biologic , agent within 30 day could , opinion investigator , impact result study . 17 . Subject medical , social psychological problem opinion investigator would preclude receive treatment procedure participate evaluation pre posttreatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Varicocele</keyword>
	<keyword>Pelvic Congestion Syndrome</keyword>
	<keyword>Pelvic Venous Incompetence</keyword>
	<keyword>Ovarian Varices</keyword>
</DOC>